托皮拉剂量优化,以通过人口药理动力学建模来有效的抗发作管理
Seolah Lee1, Hyun Chul Kim2,3, Yoonhyuk Jang1
1Laboratory for Neurotherapeutics, Department of Neurology, Comprehensive Epilepsy Center, Center for Medical Innovation, Biomedical Research Institute, Seoul National University College of Medicine and Hospital, Seoul, South Korea.
Annals of clinical and translational neurology
|December 8, 2023
概括
这项研究表明,较低的托皮拉血清水平治疗范围,低于6.5 mg/L,以减少患者的缺氧副作用. 在较低剂量时,药物的有效性会稳定下来,因此对于许多人来说,更高的剂量是不必要的.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床神经学 临床神经学
- 药理动力学 药理动力学
背景情况:
- 已确定的托皮拉血清水平治疗范围 (5-20 mg/L) 可能不适合所有患者.
- 临床观察表明,在低于推范围的水平下,药物反应显著.
- 需要根据疗效和不良事件数据来完善治疗范围.
研究的目的:
- 调查托皮拉血清水平,药物反应和不良事件之间的相关性.
- 为了建立一个更准确和量身定制的治疗范围为托皮拉.
- 为了确定最佳的血清度截止值,以获得有效性和安全性.
主要方法:
- 对389名患者 (2017年1月至2022年1月) 临床数据的回顾性分析.
- 药物反应被归类为≥50%的发作频率减少.
- 种群药理动力学建模和ROC曲线分析以确定最佳切割值.
主要成果:
- 托皮拉的平均血清水平为3.9 ± 2.8 mg/L,其中94.4%的患者显示出足够的反应.
- 在不足 (3.6 ± 2.5 毫克/升) 和足够 (4.0 ± 2.8 毫克/升) 的响应者之间,血清水平没有统计学意义.
- 显著与血清度 (p=0.04) 相关的缩症,最佳切断值为6.5 mg/L.
结论:
- 建议托皮拉的最佳治疗度低于6.5mg/L,以最大限度地降低氧风险.
- 对于低于最佳反应的患者,剂量升高是不必要的,因为在较低剂量时有效性会平稳.
- 这些发现支持对托皮拉在管理中的修订后,个性化的治疗范围.
相关概念视频
01:12Analysis of Population Pharmacokinetic Data
266
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
266
01:20Antiepileptic Drugs: Potassium Channel Activators
184
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
184
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
413
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
413
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
310
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
310
01:20Pharmacokinetic Models: Overview
709
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
709
01:26Pharmacokinetic Models: Comparison and Selection Criterion
74
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
74